Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. (PRAX): 23 pipeline candidates · 10 upcoming catalysts · ~27 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
27.1 months
D/E 0.04 · 4% dilution
Lead: Phase 3
23 candidates
10 upcoming, next in ~12d
N/A
A transparent, data-derived signal for Praxis Precision Medicines, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.6B
Cash
$536.7M
Quarterly Burn
$86.2M
Runway
27.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (23 candidates)
| Drug | Phase |
|---|---|
| 0.5mg elsunersen | Phase 3 |
| 1.0mg/kg/day PRAX-562 | Phase 3 |
| 1.5mg/kg/day PRAX-562 | Phase 3 |
| 1mg elsunersen | Phase 3 |
| 20 mg/day vormatrogine for 12 weeks | Phase 3 |
| 30 mg/day vormatrogine for 12 weeks | Phase 3 |
| 30mg PRAX-628 | Phase 2 |
| 40 mg/day vormatrogine for 12 weeks | Phase 3 |
| 60 mg ulixacaltamide | Phase 3 |
| Elsunersen | Phase 3 |
Showing 10 of 23 candidates. Sign up for full pipeline.
Upcoming Catalysts (10)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Binary FDA approval decision — outcome can sharply revalue the stock.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Binary FDA approval decision — outcome can sharply revalue the stock.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
296
Total value held
$10.38B
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 4,071,972 | $1.31B |
| janus henderson group plc | 3,543,810 | $1.14B |
| vanguard capital management llc | 2,443,888 | $787.4M |
| blackrock, inc. | 2,324,929 | $749.1M |
| fmr llc | 2,160,943 | $696.2M |
| baker bros. advisors lp | 1,753,198 | $564.9M |
| deerfield management company, l.p. | 963,351 | $310.4M |
| driehaus capital management llc | 949,225 | $305.8M |
| state street corp | 884,238 | $284.9M |
| morgan stanley | 833,491 | $268.5M |
Showing top 10 of 296 institutional holders of Praxis Precision Medicines, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Praxis Precision Medicines, Inc.'s pipeline?
Praxis Precision Medicines, Inc. (PRAX) has 23 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Praxis Precision Medicines, Inc.'s lead drug candidate?
Praxis Precision Medicines, Inc.'s most advanced tracked candidate is 0.5mg elsunersen (Phase 3) for Epileptic Encephalopathy.
What is Praxis Precision Medicines, Inc.'s next catalyst?
Praxis Precision Medicines, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: relutrigine" — expected June 30, 2026.
What is Praxis Precision Medicines, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Praxis Precision Medicines, Inc. has approximately 27.1 months of cash runway.
What is Praxis Precision Medicines, Inc.'s market capitalization?
Praxis Precision Medicines, Inc.'s market capitalization is approximately $7.6B.
Get the full picture on Praxis Precision Medicines, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.